Deals
Editas Raises $94.4 Million in First U.S. IPO of the Year
This article is for subscribers only.
Editas Medicine Inc., the gene-editing drugmaker backed by Bill Gates and GV, raised $94.4 million in the first U.S. initial public offering of 2016, pricing the shares at the low end of the marketed range.
The company sold 5.9 million shares for $16 apiece, according to data compiled by Bloomberg, after offering them for $16 to $18 each. Shares of Editas will begin trading Wednesday on the Nasdaq Stock Market under the symbol EDIT.